Edition:
United States

Delcath Systems Inc (DCTH.OQ)

DCTH.OQ on NASDAQ Stock Exchange Capital Market

0.03USD
22 May 2017
Change (% chg)

$-0.00 (-14.78%)
Prev Close
$0.03
Open
$0.03
Day's High
$0.03
Day's Low
$0.03
Volume
12,378,205
Avg. Vol
2,114,748
52-wk High
$6.45
52-wk Low
$0.03

DCTH.OQ

Chart for DCTH.OQ

About

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System... (more)
No analyst recommendations are available for DCTH.OQ.

Overall

Beta: 1.35
Market Cap(Mil.): $5.34
Shares Outstanding(Mil.): 167.88
Dividend: --
Yield (%): --

Financials

  DCTH.OQ Industry Sector
P/E (TTM): -- 31.06 17.37
EPS (TTM): -8.98 -- --
ROI: -638.24 12.87 -5.89
ROE: -756.05 15.33 -5.30

BRIEF-Delcath Q1 loss per share $0.25

* Delcath systems - anticipates cash remaining in controlled accounts after transaction will be sufficient to fund operating activities through end of 2017 Source text for Eikon: Further company coverage:

May 09 2017

BRIEF-Delcath says anticipates cash remaining in controlled accounts able to fund operating activities through 2017 end

* Delcath says anticipates cash remaining in controlled accounts, after close of April 2 repurchase agreements, to be able to fund operating activities through 2017 end Source text for Eikon: Further company coverage:

Apr 03 2017

BRIEF-Delcath announces 2016 financial results

* Believes it has sufficient capital and access to committed capital to fund its operating activities through q1 of 2018 Source text for Eikon: Further company coverage:

Mar 29 2017

BRIEF-Delcath systems's independent registered public accounting firm issued report

* Delcath Systems - Co's independent registered public accounting firm issued report on March 28 regarding audit of co's financial statements as of Dec 31, 2016

Mar 29 2017

BRIEF-Delcath announces special protocol assessment agreement with FDA for pivotal trial with Melphalan/HDS in intrahepatic cholangiocarcinoma

* Delcath announces special protocol assessment agreement with FDA for pivotal trial with Melphalan/HDS in intrahepatic cholangiocarcinoma Source text for Eikon: Further company coverage:

Mar 27 2017

BRIEF-Delcath Systems enters agreement with holders of more than 55 pct of aggregate principal amount of senior secured convertible notes Due Dec 29, 2017

* Delcath Systems - co, holders of more than 55 pct of aggregate principal amount of senior secured convertible notes due Dec 29, 2017 entered agreement

Feb 23 2017

BRIEF-Barbra C. Keck became CFO of Delcath Systems effective Feb. 21- SEC filing

* Effective February 21, 2017, Barbra C. Keck became chief financial officer of company - SEC filing Source text for Eikon: Further company coverage: ;))

Feb 22 2017

BRIEF-Empery Asset Management LP dissolves passive stake in Delcath Systems

* Empery Asset Management LP dissolves passive stake in Delcath Systems Inc as of Dec 30, 2016 - SEC filing

Jan 31 2017

BRIEF-Delcath announces patient treatment in intrahepatic Cholangiocarcinoma study

* Delcath Systems Inc - patient treatment, data collection for intrahepatic cholangiocarcinoma (ICC) cohort of European Phase 2 HCC/ICC study is ongoing

Jan 12 2017

More From Around the Web

Earnings vs. Estimates